Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro) - A Phase II Drug-repurposing Study

NCT07365423 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT07365423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07365423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro) - A Phase II Drug-repurposing Study
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
April 24, 2026
Completion date
October 31, 2030
Enrollment
42 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent prostate cancer